Curative Biotech says US patent office allows metformin eye-drop application for retinal degeneration

PUBT · 1d ago
Curative Biotech says US patent office allows metformin eye-drop application for retinal degeneration
  • Curative Biotechnology disclosed a U.S. patent application was allowed for topical metformin eye drops targeting retinal degeneration.
  • Claims cover age-related macular degeneration, retinal pigment epithelium degeneration, Stargardt’s disease, using formulations designed for ocular delivery.
  • The allowances expand intellectual property tied to technology licensed exclusively worldwide from the National Eye Institute, part of the NIH.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curative Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609110700PRIMZONEFULLFEED9825009) on September 11, 2026, and is solely responsible for the information contained therein.